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Abstract
Background: Co-occurring substance use increases the risk of hospitalisation in people with severe mental illness,
whereas Assertive Community Treatment (ACT) generally reduces hospitalisation in patients with severe mental
illness and high inpatient service use. Because the superiority of ACT over standard services amongst patients with
problematic substance use is uncertain, the present study examined inpatient service use amongst patients with
and without problematic substance use in the 2 years before and the 2 years after they enrolled into ACT teams.
Methods: This naturalistic observational study included 142 patients of 12 different ACT teams throughout Norway.
The teams assessed the patients upon enrolment into ACT using clinician-rated and self-reported questionnaires.
We obtained hospitalisation data from the Norwegian Patient Register for the 2 years before and the 2 years after
enrolment into ACT. We used linear mixed models to assess changes in hospitalisation and to explore associations
between problematic substance use and changes in hospitalisation, controlling for socio-demographic and clinical
characteristics.
Results: A total of 84 (59 %) participants had problematic substance use upon enrolment into the ACT teams. In
the 2 years after ACT enrolment both participants with and without problematic substance use experienced a
reduction in total inpatient days. Those with problematic substance use also had fewer involuntary inpatient days.
Exploratory analyses suggested that symptom severity and functioning level interacted with problematic substance
use to influence change in total inpatient days.
Conclusion: These findings may suggest that ACT teams successfully support people with complex mental health
problems in the community, including those with problematic substance use, and thereby contribute to a
reduction in inpatient service use.
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Background
Substance use problems are more common amongst pa-
tients with schizophrenia than in the general population
[1] with reported lifetime prevalence ranging from 47 to
60 % [1–3] and current prevalence ranging from 27 to
41 % [2, 4]. Substance use problems amongst people
with schizophrenia also increase the risk of many nega-
tive outcomes, including increased hospital readmissions
[5, 6], number of inpatient days [7], and involuntary ad-
missions [8].
Assertive Community Treatment (ACT) is an inten-
sive, multidisciplinary, community-based mental health
service model that reduces hospitalisation amongst
people with severe mental illnesses, such as schizophre-
nia, that are high users of inpatient care [9]. Many also
suffer comorbidities, do not engage successfully with
standard mental health services [10], and experience re-
current cycles of relapse, hospital readmissions [10, 11],
and high use of inpatient services [9, 12, 13]. The ACT
approach provides more flexible and intensive support
than generic mental health services, delivering evidence-
based, individually-tailored interventions in the commu-
nity [10, 14]. The prevalence of current substance abuse
in ACT populations ranges from 49 to 72 % [15–18],
higher than other mental health outpatient groups.
Although ACT is generally superior to standard
community-based services in reducing hospitalisation,
the evidence amongst patients with co-occurring sub-
stance misuse problems is equivocal [19–21]. Few stud-
ies have compared hospitalisation amongst patients with
and without co-occurring substance misuse problems
before and after they engaged with ACT. One previous
study that explored associations between patient charac-
teristics and changes in hospitalisation, found that
changes in total and involuntary inpatient days were not
associated with the severity of alcohol or drug use prob-
lems. [22] Nevertheless, because substance use increases
the risk of hospitalisation, patients with co-occurring
substance misuse problems are likely to be higher users
of inpatient services. We therefore hypothesized that
ACT would have a greater impact on hospitalisation
amongst this group, even though ACT has not been
proven to effectively reduce substance use [19].
Aims and research questions
The aims of this study were to compare inpatient ser-
vice use (new admissions, total inpatient days, and in-
voluntary inpatient days) amongst ACT patients with
and without problematic substance use and to explore
associations between changes in inpatient service use
and patient characteristics, including problematic sub-
stance use.
Our research questions were: First, are there differ-
ences in inpatient service use amongst patients with and
without problematic substance use during the 2 years
before and the 2 years after ACT enrolment? Second, is
problematic substance use associated with changes in
hospitalisation when adjusted for patient characteristics?
Methods
Design
We used a naturalistic observational study on ACT in
Norway. For 142 patients of 12 Norwegian ACT teams,
we combined cross-sectional socio-demographic and
clinical data from enrolment into ACT and longitudinal
hospitalisation data in the 2 years before and the 2 years
after enrolment. Due to the nature of the funding and
the implementation of the ACT model in Norway, we
could not conduct a randomized trial.
Recruitment and sample
Between 1999 and 2008 a national program took place
in Norway to improve mental health services. However,
the evaluation of the program concluded that, despite
major investments, expansion and reorganisations, the
services were lacking continuity, they were fragmented,
and approximately 4000 people with severe mental ill-
ness were not well engaged with services despite their
need for treatment and follow-up [23]. Subsequently, in
2009, the National Health Authorities decided to fund
the implementation of ACT teams across Norway to im-
prove services for people with severe mental illness who
suffered comorbidities such as substance misuse and
needed more comprehensive services. A history of high
inpatient service use was not mandatory for being taken
on by the ACT teams because the aim was to reach
people who were not well engaged with services. This
could potentially include patients who had not been fre-
quently admitted to hospital.
Between December 2009 and February 2011, 12 ACT
teams started up across the country. Patient inclusion
criteria included: 18 years or older, severe mental illness
(schizophrenia, schizoaffective, other psychotic disorder,
bipolar affective disorder), impaired level of functioning,
and need for long-term, comprehensive follow-up by
mental health and social welfare services.
Patients with co-occurring substance misuse were in-
cluded if this was not the primary diagnosis.
A severe mental illness was diagnosed by referring
agencies and was based on International Statistical Clas-
sification of Diseases and Related Health Problems 10th
Revision (ICD-10) criteria [24] for 69 participants
(49 %); upon the “Mini International Neuropsychiatric
Interview Plus” (MINI Plus) [25], or the “Structured
Clinical Interview for DSM-IV Axis I Disorders” (SCIDI)
[26], or other non-specified diagnostic instrument for 6
participants (4 %) while it was unknown how 27
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participants (19 %) were diagnosed. Data were missing
for 40 participants (28 %).
The use of the Global Assessment of Functioning (GAF)
scale is mandatory in specialised mental health care in
Norway but not in primary care. The referral agencies
therefore assessed the level of functioning based on clin-
ical evaluation or on the GAF scale [27, 28].
For the present study we limited inclusion to the ACT
teams’ first year of operation. A total of 337 patients
enrolled into the 12 teams and all patients were invited
to participate in the study; 202 (60 %) gave written
informed consent to participate after the teams had
explained the procedures; and 142 participants (42 %)
received ACT services for at least 2 years and were
thus eligible for this study.
All 142 participants remained in contact with the
teams during the 2 year follow-up period. A total of 12
participants (8 %) were admitted to inpatient substance
use treatment in the 2 years before and/or after being
taken on by the ACT teams. While three participants
only were admitted in the 2 years before, seven partici-
pants were only admitted during ACT follow-up and
two participants were admitted both before and during
ACT follow-up. The mean number of inpatients days
spent in substance abuse treatment in the 2 years before
ACT was 17.4 days (SD 11.1) and median 13 days
(min-max: 7–34 days). The mean number of inpatient
days spent in substance abuse treatment during ACT
follow-up was 39.3 days (SD 53.0) and median
11.0 days (min-max: 1–133 days). We have no data
on periods of incarceration.
Participants and non-participants did not differ in
age, gender, diagnosis of severe mental illness, or num-
ber of people being subject to involuntary outpatient
treatment. Participants did, however, have less severe
symptoms (mean score ± Standard Deviation [SD] on
Global Assessment of Functioning – Symptom Scale
[GAF-S], 41.4 ± 10.2 versus 38.8 ± 10.0, p = 0.028) and
better functioning (mean score ± SD Global Assessment
of Functioning – Function Scale [GAF-F], 39.7 ± 8.3
versus 37.6 ± 8.9, p = 0.036). Upon enrolment into ACT,
fewer participants had problematic substance use (n = 83
versus 128, 59 versus 70 %, p = 0.034) compared to non-
participants.
Most participants were male (n = 94, 67 %), and of
Norwegian origin (n = 114, 84 %). They had a mean age
of 39.8 ± 10.6 years. Most were single (n = 106, 75 %),
living alone (n = 91, 65 %), and unemployed (n = 118,
83 %). Few had completed higher education (n = 12,
9 %). Almost all had a severe mental illness (accord-
ing to the ICD-10 criteria, n = 124, 94 %) such as
schizophrenia (F20-29, n = 115, 87 %) or bipolar dis-
order (F31, n = 9, 7 %). The mean age of illness onset
was 25.9 ± 8.7 years. Overall, participants experienced
severe symptoms (GAF-S 41.4 ± 10.2) and poor func-
tioning (GAF-F 39.7 ± 8.3) at the point of enrolment
(these scales are described in more detail below).
Measures
Problematic substance abuse was assessed using two
self-reported questionnaires, The Alcohol Use Disorder
Identification Test (AUDIT) [29] and the Drug Use
Disorder Identification Test (DUDIT) [30], and two
clinician-rated questionnaires, the Alcohol Use Scale
(AUS) [31] and the Drug Use Scale (DUS) [32]. The
AUDIT comprises 10 items with total score from 0 to
40 and the DUDIT comprises 11 items with total
score from 0 to 44. Scores above specific cut-offs
(AUDIT: men 8, women 6; DUDIT: men 6, women 2)
indicate problematic substance use and higher scores
indicate greater severity. The AUS and the DUS are
5-point scales with scores from 1 (no use) to 5 (se-
vere dependence), with score 3 or higher indicating
problematic substance use.
The ACT team clinicians also collected socio-
demographic data using a form developed by the re-
search group (life situation and health-questionnaire),
and patients’ global symptom and functioning levels
using the Global Assessment of Functioning (GAF) scale
[27], split version (symptoms scale [GAF-S] and func-
tioning scale [GAF-F]) [28]. The GAF scales range from
0 to 100, and higher scores indicate less severe symp-
toms and better functioning. The expanded version of
the Brief Psychiatric Rating Scale (BPRS) [33, 34] was
used to assess the frequency and severity of psychiatric
symptoms. The BPRS comprises 24 items, yielding four
factors (positive symptoms, negative symptoms, agitation
mania, and anxiety/depressive symptoms) [35]. Each
item is rated from 1 (not present) to 7 (extremely se-
vere). Everyday functioning was measured with the re-
vised version of the Practical and Social Functioning
Scale (PSF) [36]. PSF-revised comprises 32 items with a
mean total score ranging from 0 to 8. Higher scores in-
dicate better functioning.
Procedures
We obtained data from the Norwegian Patient Register
on inpatient service use in mental health hospitals for
the 142 patients in the 2 years before and the 2 years
after enrolment into ACT. We used data from both
clinician-rated and self-reported questionnaires. The
ACT teams collected socio-demographic and clinical
data when patients enrolled into teams through inter-
views with patients, care givers, professionals, and from
direct observations and case-note reviews. Patients
responded to the self-reported questionnaires (the
AUDIT and the DUDIT) alone or together with a team
member at enrolment onto the teams. The teams
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repeated the AUS and the DUS after 2 years with ACT
while the participants in the study completed the
AUDIT and the DUDIT after 2 years of ACT follow-up.
Fidelity of Norwegian ACT teams
The Norwegian teams’ fidelity to the ACT model was
assessed using the Tool for Measurement of Assertive
Community Treatment (TMACT) [14] 12 and 30 months
after establishment. The mean TMACT scores at
12 months ranged from 2.7 to 3.7, indicating low to
moderate fidelity and at 30 months the scores ranged
from 3.1 to 4.1, indicating moderate to high fidelity. The
key principles of ACT, mainly measured on the subscales
organization & structure, core team members, and core
practices, represent the greatest differences with Norwe-
gian standard mental health services. The ratings on
these subscales showed moderate to high fidelity at both
12 and 30 months. Substance abuse specialist was
present in 11 teams at 12 and 30 months fidelity evalu-
ation. The mean TMACT scores on the five subscales
relating to substance abuse specialist and Integrated
Dual Disorder Treatment (IDDT) showed moderate to
high fidelity. However, the scores on the different items
showed large variations between teams (scores ranged
1–5, indicating none to full implementation).
Statistical analysis
We assessed differences in demographic and clinical
characteristics between groups by Fisher’s exact test for
dichotomous variables, Chi-square test for categorical
variables, Student’s T-test for symmetrically distributed
continuous variables, and Mann–Whitney U test for
skewed continuous variables.
Three dependent variables assessed the change in
hospitalisation; new admissions, total inpatient days
and involuntary inpatient days. We defined these
three dependent variables as the difference between
the number 2 years before and the number 2 years
after enrolment into ACT.
We analysed the difference between participants with
and without problematic substance use in the three
dependent variables by estimating linear mixed models,
one for each variable. The models contained fixed effect
for each patient group (with and without problematic
substance use). Random effects for intercepts were in-
cluded into the models to adjust for possible cluster ef-
fect due to intra-ACT correlations.
In the exploratory multivariate linear mixed models,
we adjusted the associations between problematic sub-
stance use [Y/N] and the three dependent variables for
demographic (age, gender) and clinical factors (involun-
tary outpatient treatment [Y/N], the four BPRS sub-
scales, GAF-S, GAF-F, and PSF). In the same exploratory
analyses, we also assessed interactions between the
problematic substance use variable and demographic
and clinical characteristics in all three models. We used
Akaike’s Information Criteria [37] (the smaller the bet-
ter) in model reduction. We applied standard residual
diagnostic tests to assess the assumption of linear mixed
models. The residuals were somewhat skewed, therefore
we generated bootstrap based inference as well. How-
ever, as the differences were negligible, the results from
the linear mixed model were presented. We considered
these exploratory analyses as hypothesis-generating and
not hypothesis-testing; therefore we did not correct for
multiple tests.
We imputed missing values on PSF items (n = 14,
0.3 % of cases) by generating the empirical distribution
for each item and drawing a random number from that
distribution to replace the missing value. The process
was repeated until all missing values were imputed. The
GAF-S and GAF-F scores were close to normally distrib-
uted, and missing values (both n = 4, 2.8 % of cases)
were therefore imputed by drawing a random number
from the corresponding normal distribution. The BPRS
was completed for 98.6 % of the participants and thus
we imputed no scores. As the number of imputed values
was low, no sensitivity analysis was performed.
We used the Statistical Analysis System version 9.3
(SAS Institute, Cary, NC USA) to estimate linear mixed
models and the Statistical Package for Social Science
version 22 (SPSS, Chicago, IL USA) for other statistical
analyses. All tests were two-sided, considering P-values
below 0.05 as statistically significant.
Results
Classification and characteristics of participants with and
without problematic substance use
We based classification of problematic substance use pri-
marily on the AUDIT and DUDIT scores. Seventy-two
participants (51 %) had a score above cut-off on one or
both scales. The mean AUDIT and DUDIT scores ± SD
for participants with scores above cut-off indicated severe
problems (AUDIT 17.1 ± 7.6 and DUDIT 21.0 ± 10.3).
For participants who had not completed the AUDIT
and DUDIT (n = 12, 8 %) or who had a score below cut-
off (n = 58, 41 %), we added the clinician-rated AUS and
DUS. For nine participants the clinicians gave a score of
3 or higher on the AUS and/or the DUS, and we classi-
fied these participants as having problematic substance
use. In addition, we identified three participants with
missing AUS and DUS as having problematic substance
use based on the clinician-rated assessment of substance
abuse in the life situation and health-questionnaire.
Thus, 84 (59 %) participants had problematic sub-
stance use, while 58 (41 %) did not. The most commonly
used substances were alcohol (n = 54, 74 %), amphet-
amine (n = 34, 54 %) and cannabis (n = 30, 52 %).
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After 2 years with the ACT teams, 78 patients (93 %)
still had problematic substance use. Four (7 %) of the 58
participants who were originally classified as not having
a problem met the criteria for problematic substance use
on follow-up, while six of the 84 participants (7 %) who
had problematic substance use upon ACT enrolment no
longer met the criteria after 2 years.
The mean scores ± SD on the AUDIT (16.2 ± 7.7) and
the DUDIT (22.8 ± 10.0) for those who scored above
cut-off again indicated severely problematic substance
use at 2 years follow-up.
Table 1 presents the characteristics of each group
upon ACT enrolment. Participants with problematic
substance use were more likely to be of Norwegian ori-
gin, under involuntary outpatient treatment, and to have
a lower level of educational achievement than partici-
pants without problematic substance use. They also had
more severe psychiatric symptoms, in particular manic/
agitated symptoms, and poorer functioning than partici-
pants without problematic substance use.
Changes in hospitalisation
Of the 142 participants in our study, 128 (90 %) were ad-
mitted to mental health hospital in the 2 years before
and/or the 2 years after being taken on by the ACT
teams. A total of 14 participants (10 %) were not admit-
ted at all. Of these 14 participants, nine (64 %) did have
problematic substance use while five (36 %) did not.
Table 2 shows the mean number of new admissions,
mean total inpatient days and mean involuntary in-
patient days in the 2 years before and the 2 years after
ACT enrolment for all participants with and without
problematic substance use. According to the linear
mixed models unadjusted for patient characteristics, the
mean number of new admissions did not change after
ACT enrolment in either group, but both groups experi-
enced reduction in total inpatient days. Patients with
problematic substance use also had fewer involuntary in-
patient days after being taken on by ACT.
Associations between problematic substance use and
changes in hospitalisation
We found only small differences between the ACT
teams regarding changes in all hospital outcomes, as in-
dicated by the low intra-class correlation coefficients
(new admissions 2.7 %, total inpatient days 3.7 %, and
involuntary inpatient days 1.4 %), but we adjusted all
models for cluster effects.
No significant interactions occurred between problematic
substance use and the adjustment variables (demographic
characteristics [age, gender] or clinical characteristics [BPRS
four factors, GAF-S, GAF-F and PSF]).
The multivariate exploratory linear mixed models
showed no associations between problematic substance
use and changes in the number of new admissions or in-
voluntary inpatient days but significant associations with
change in total inpatient days emerged (Table 3). Symp-
tom severity and functioning levels influenced these
associations.
Less severe symptoms were associated with greater re-
duction in total inpatient days amongst participants
without problematic substance use, but no association
occurred between symptom severity and changes in total
inpatient days amongst participants with problematic
substance use (see Fig. 1).
Participants with less seriously impaired functioning
(GAF-F score 45 or above) and problematic substance
use experienced a reduction in total inpatient days
while participants without problematic substance use
with similar functioning level accrued more inpatient
days in the 2 years with ACT compared to the 2
years before (see Fig. 2).
Additionally, amongst participants with more severely
impaired functioning (GAF-F score up to 50) and prob-
lematic substance use, better functioning was associated
with greater reduction in total inpatient days. This asso-
ciation was not found amongst participants with prob-
lematic substance use and less severely impaired
functioning or amongst participants without problematic
substance use.
We explored the linear mixed models further by
adjusting for the change in status of 10 participants re-
garding their problematic substance use (six participants
who had problematic substance use upon ACT enrol-
ment no longer met the criteria after 2 years and four
who did not have problematic substance use originally
had developed these at the 2 year assessment point).
The results remained unchanged.
Discussion
A total of 84 (59 %) participants had problematic sub-
stance use when they enrolled into the ACT teams and
after 2 years with ACT, 78 (93 %) participants still had
ongoing, severe substance use.
We found no changes in the number of new admis-
sions after the participants enrolled into the ACT teams,
but total inpatient days decreased. Participants with
problematic substance use also had fewer involuntary in-
patient days during ACT follow-up.
Exploratory analyses showed that changes in total in-
patient days differed for participants with compared to
participants without problematic substance use, and
symptom severity and functioning level upon ACT en-
rolment influenced these changes.
Changes in hospitalisation
Our results confirm earlier reports in that total inpatient
days were reduced during ACT, but without significant
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reduction in the number of admissions [9]. The reduction
in total and involuntary inpatient days amongst partici-
pants with problematic substance use occurred despite
on-going substance use. This may be explained by their
high level of inpatient service use before being taken on
by the ACT teams. [9] Our findings indicate that ACT
Table 1 Socio-demographic and clinical characteristics of participants with and without problematic substance use on ACT
enrolment
Socio-demographic characteristics: Non-substance group (N = 58) Substance group (N = 84)
N % N % P-value
Sex (male) 34 59.6 60 71.4 0.151a
Age, mean (SD) 41.7 (11.7) 38.4 (9.6) 0.068c
Ethnicity 0.001a
Norwegian 38 70.4 76 92.7
Marital status 0.056b
Unmarried 38 65.5 68 81.0
Married/cohabitant 5 8.6 7 8.3
Divorced 15 25.9 9 10.7
Education 0.003b
Completed primary school 29 55.8 47 58.8
Completed upper secondary school 13 25.0 31 38.8
Completed higher education 10 19.2 2 2.5
Employment status 0.291b
Unemployed 45 77.6 73 86.9
Competitive job/study 5 8.6 3 3.6
Other 8 13.8 8 9.5
Living situation 0.625b
Alone 38 65.5 53 63.9
With family 14 24.1 17 20.5
Staffed housing/supported housing/Institutions (hospital,
prison, hospice)/Homeless/unstable living situation
6 10.3 13 15.7
Clinical characteristics:
Diagnosis 0.710a
Severe mental illness (yes) 47 95.9 77 92.8
Community treatment order (yes) 13 22.4 38 45.8 0.005a
Age of onset psychiatric illness, mean (SD) 27.3 9.4 24.8 8.1 0.135d
Psychiatric symptoms, mean (SD)
BPRS mean total score, mean (SD) 2.24 0.66 2.60 0.86 0.015d
BPRS positive symptoms, mean (SD) 2.23 1.14 2.65 1.34 0.075d
BPRS negative symptoms, mean (SD) 2.59 1.18 2.43 1.14 0.432d
BPRS agitation mania, mean (SD) 1.78 0.77 2.42 1.19 0.001d
BPRS anxiety/depressive symptoms, mean (SD) 2.63 1.10 2.77 0.95 0.425c
Global level of functioning – symptom scale (GAF-S), mean (SD) 43.6 10.6 39.8 9.8 0.032c
Global level of functioning – functioning scale (GAF-F), mean (SD) 40.8 8.6 38.9 8.1 0.161c
Level of functioning (PSF), mean (SD) 4.63 1.62 4.05 1.50 0.033c
aFischer’s Exact Test
bChi-square
cStudent’s T-test
dMann–Whitney U Test
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successfully reduces inpatient service use amongst patients
with and patients without problematic substance use.
Changes in inpatient service use could also be influ-
enced by temporal changes in national policies and bed
availability. This threat to validity emerges particularly
in uncontrolled pre-post studies such as ours. From
2009 to 2013, a reduction of only 13 % in inpatient
mental health beds and 15 % in total inpatient days oc-
curred in Norway [38], and fluctuations in the number
of involuntary inpatient days were minor [39]. Add-
itionally, national data from 2009 [40] to 2013 [38]
showed that high users of inpatient services, the major-
ity of whom suffer severe mental illness like schizo-
phrenia, spent an average of 75–83 days in hospital per
year. This is similar to the level of total inpatient days
per year in the 2 years before ACT in our study but al-
most twice as high as the number of total inpatient
days per year during the ACT follow-up. This suggests
that national changes in policies and bed availability
cannot fully explain the reductions in our study and
that the changes do not represent temporal effects.
However, we cannot exclude that the changes observed
in this study are regression to the mean.
Qualitative data have suggested that the ACT teams
identified participants in an early state of relapse,
thereby avoiding severe deteriorations that might have
required long-term admissions [41].
Participants may also have been discharged earlier be-
cause of the availability of support and services from
high intensity ACT teams.
Associations between problematic substance use and
changes in hospitalisation
Exploratory linear mixed models showed no associa-
tions between problematic substance use and changes
in the number of new admissions, or between
Table 3 Linear mixed models: Associations between problematic substance use and changes in hospitalisation (n = 128)
Variables New admissions Total inpatient days Involuntary inpatient days
Regression coefficient (SE) p-value Regression coefficient (SE) p-value Regression coefficient (SE) p-value
Problematic substance use (Y/N) 0.35 (0.91) 0.698 −113.00 (151.19) 0.456 56.30 (30.21) 0.065
BPRS Positive symptoms 0.35 (0.45) 0.439 −11.01 (16.23) 0.499 −13.93 (14.78) 0.348
BPRS negative symptoms −0.45 (0.38) 0.230 19.83 (13.97) 0.159 17.70 (12.71) 0.166
BPRS agitation mania 0.56 (0.51) 0.277 −34.80 (19.49) 0.077 −35.55 (17.35) 0.043
BPRS anxiety/depressive symptoms −0.88 (0.43) 0.042 −20.58 (15.24) 0.180 −19.15 (14.18) 0.180
GAF-S 0.16 (0.07) 0.027 3.46 (3.38) 0.308 −2.45 (2.36) 0.301
GAF-F −0.12 (0.08) 0.151 −9.18 (4.38) 0.037 −0.68 (2.80) 0.809
PSF – – 15.02 (11.40) 0.191 8.68 (10.16) 0.395
Age 0.01 (0.04) 0.819 −1.95 (1.56) 0.214 −0.46 (1.45) 0.754
Gender −0.58 (0.89) 0.514 51.78 (32.46) 0.114 53.40 (29.41) 0.072
Problematic substance use*GAF-S −8.25 (4.52) 0.071*
Problematic substance use*GAF-F 12.31 (5.77) 0.035*
*P-values below 0.10 were considered significant for interactions
Table 2 Hospitalisation during two years before and after ACT: participants with and without problematic substance use
Before taken on by ACT After taken on by ACT Change before-after taken on by ACT
Mean SD Mean SD Meana 95 % confidence interval P-valueb
New admissions Non-problematic substance usec 2.79 3.06 2.78 5.07 0.05 −1.31 to 1.40 0.945
Problematic substance used 3.71 4.48 3.26 4.48 0.45 −0.68 to 1.57 0.436
Total inpatient days Non-problematic substance usec 106.12 133.83 50.55 57.18 58.24 7.83 to 108.64 0.024
Problematic substance used 131.15 167.51 69.01 88.54 64.09 21.90 to 106.28 0.003
Involuntary inpatient
days
Non-problematic substance usec 51.53 116.51 20.78 40.07 29.96 −14.92 to 74.83 0.191
Problematic substance used 101.05 163.09 47.57 75.99 55.69 19.16 to 92.22 0.003
aPositive means indicate mean reduction in outcome after being taken on by ACT compared to before while negative means indicate mean increase in outcome
bAnalyses of change using linear mixed models, unadjusted model
cNon-substance group n = 58 (41 %), d Substance group n = 84 (59 %)
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problematic substance use and change in involuntary
inpatient days despite a significant reduction amongst
participants with problematic substance use and not
amongst participants without problematic substance
use. However, total inpatient days changed differently
for participants with problematic substance use com-
pared to those without in the sense that symptom se-
verity and functioning level influences these changes.
These results were from exploratory analyses per-
formed in a small sample, aiming to generate hypothesis.
This aspect of our study may be under-powered and
need replication before conclusions can be drawn.
Strengths and limitations
Strengths of our study included: data from 12 ACT
teams operating in both urban and rural areas across
Norway; instruments with good psychometric proper-
ties; and 4 years of longitudinal data. Weaknesses in-
cluded: the observational design, which weakens causal
interpretations; the high rate of non-participation that
could lead to an overestimation of change in hospital-
isation in one or both groups because fewer patients
with more severe illness participated.; potential errors
in the data from the Norwegian Patient Register; all
teams were newly established which may have had posi-
tive effects in that the ACT staff were motivated, enthu-
siastic and had (at least in the start-up phase) a low
patient:staff-ratio. The negative effects may be that they
implemented an unfamiliar model (to the Norwegian
health system), did not have all necessary resources in
place and lacked skills and training in providing evi-
dence based treatment. Further limitations were the use
of clinician-rated instruments and the large number of
clinicians involved in the assessments; and the pre-
sumed accuracy of our multi-method diagnosis of prob-
lematic substance use which may have caused an
under- or over representation of people with problem-
atic substance use and thereby influenced an under- or
overestimation of change in hospitalisation.
Conclusion
This study found that participants with and without
problematic substance use had significant reductions
in inpatient days during the ACT follow-up. In
addition, those with problematic substance use also
had fewer involuntary inpatient days, despite on-going
problematic substance use. These findings may sug-
gest that ACT teams successfully support people with
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Fig. 1 Association between changes in total inpatient days and level of symptoms for both groups: Black line: Participants without problematic
substance use. Grey line: Participants with problematic substance use
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complex mental health problems in the community,
including those with problematic substance use, and
thereby contribute to a reduction in inpatient service
use.
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